Page 2 - Mike Hencke News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biogen Inc : Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting

TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts

United statesUnited kingdomNew zealandChristophera viehbacherLibby holmanHaruo naitoMike henckeNatacha gassenbachAlzheimer clinical trial consortiumDrug administrationCommunications departmentExchange commissionWashington university school of medicineNational medical products administrationInternational conference on alzheimerNational institutes of health

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

New zealandUnited kingdomUnited statesMike henckeLibby holmanNatacha gassenbachAlzheimer clinical trial consortiumCommunications departmentWashington university school of medicineDrug administrationBiogen incAdvisory committeeEisai incInvestor relations departmentDevices agencyNational institutes of health

Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

TOKYO and CAMBRIDGE, Mass., Mar 31, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that three additional detailed analyses from the Phase IIb clinical study (Study

United kingdomNew zealandUnited statesLibby holmanStefan klotterMike henckeNatacha gassenbachAlzheimer network trials unitMinistry of healthAlzheimer researchTranslational researchDevices agencyInvestor relations departmentDrug administrationUnited nations sustainable development goals sdgsEisai inc

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNew zealandMike henckeLibby holmanNatacha gassenbachTranslational researchEuropean medicines agencyNational medical products administrationEisai europe ltdExchange commissionNational institute onUnited nations sustainable development goals sdgsAlzheimer network trials unitPublic relations departmentInvestor relations department

New Data Presented at AD/PD™ 2023 Show Biogen s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer s Disease

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau. | March 29, 2023

Vastra gotalands lanUnited statesUnited kingdomPriya singhalJack coxMike henckeExchange commissionBiogen incAlzheimer associationInternational conference on alzheimerHead of development at biogenInternational conferenceExecutive vice presidentSafe harborTau proteinAccessed march